# Phase 4 IOP Signals Associated With ILUVIEN®

> **NCT02424019** · PHASE4 · COMPLETED · sponsor: **Alimera Sciences** · enrollment: 153 (actual)

## Conditions studied

- Diabetic Macular Edema (DME)

## Interventions

- **DRUG:** ILUVIEN 0.19 MG

## Key facts

- **NCT ID:** NCT02424019
- **Lead sponsor:** Alimera Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-06
- **Primary completion:** 2020-07-29
- **Final completion:** 2020-07-31
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2022-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02424019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02424019, "Phase 4 IOP Signals Associated With ILUVIEN®". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02424019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*